Published in Pharmacogenomics J on January 01, 2001
Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav (2014) 0.94
Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry (2015) 0.94
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Pharmacogenetics in mood disorder. Curr Opin Psychiatry (2005) 0.84
Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs (2013) 0.83
Lithium: a key to the genetics of bipolar disorder. Genome Med (2009) 0.80
Predictors of lithium response in bipolar disorder. Ther Adv Chronic Dis (2011) 0.80
Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines. Pharmacogenomics J (2016) 0.77
Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci (2014) 0.76
Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics (2010) 0.75
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry. EPMA J (2017) 0.75
A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60
Tolerance and withdrawal with zolpidem. Lancet (1993) 1.97
Representation of the temporal envelope of sounds in the human brain. J Neurophysiol (2000) 1.96
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry (2000) 1.60
The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol Psychiatry (2008) 1.56
Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry (2001) 1.56
Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry (1996) 1.55
Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry (1999) 1.53
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. J Clin Psychiatry (1999) 1.43
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry (1998) 1.29
Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res (1999) 1.29
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res (1999) 1.25
[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry (1995) 1.23
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol (2000) 1.17
Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry (2005) 1.17
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry (2001) 1.11
Clock genes beyond the clock: CLOCK genotype biases neural correlates of moral valence decision in depressed patients. Genes Brain Behav (2007) 1.10
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis (2006) 1.08
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci (1999) 1.06
Psychiatric disorders in the families of patients with obsessive-compulsive disorder. Psychiatry Res (1992) 1.06
High risk for obstructive sleep apnea in truck drivers estimated by the Berlin questionnaire: prevalence and associated factors. Chronobiol Int (2004) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res (1996) 1.03
Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry (1999) 1.02
Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res (1992) 1.01
How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol (1997) 1.00
Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett (2012) 0.99
Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet (1999) 0.98
Immunogenetics of the Lennox-Gastaut syndrome: frequency of HL-A antigens and haplotypes in patients and first-degree relatives. Epilepsia (1975) 0.97
Morning sunlight reduces length of hospitalization in bipolar depression. J Affect Disord (2001) 0.97
Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol Psychiatry (1993) 0.96
Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry (1998) 0.95
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry (2001) 0.93
The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res (1998) 0.93
Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet (1999) 0.93
Response to SSRIs and role of the hormonal therapy in post-menopausal depression. Eur Neuropsychopharmacol (2006) 0.92
'Theory' of mind impairment in patients affected by schizophrenia and in their parents. Schizophr Res (2009) 0.91
DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. Am J Med Genet (2001) 0.90
Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disord (2000) 0.90
Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol (1997) 0.90
Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry (1996) 0.90
Morbidity risk for obsessive-compulsive spectrum disorders in first-degree relatives of patients with eating disorders. Am J Psychiatry (2001) 0.90
Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res (2000) 0.89
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry (2001) 0.89
A genetic study of affective disorders. Acta Psychiatr Scand (1977) 0.88
Circadian clock gene Per3 variants influence the postpartum onset of bipolar disorder. Eur Psychiatry (2011) 0.87
Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Mol Psychiatry (2000) 0.87
Symptomatologic analysis of psychotic and non-psychotic depression. J Affect Disord (1999) 0.87
Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatr Scand (1998) 0.87
No association of the Ser/Cys311 DRD2 molecular variant with schizophrenia using a classical case control study and the haplotype relative risk. Schizophr Res (1997) 0.87
A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol (2005) 0.87
d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect (1994) 0.87
A family study of schizotypal disorder. Schizophr Bull (1995) 0.86
Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer (2003) 0.86
Assortative mating and affective disorders. J Affect Disord (1979) 0.86
Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol (1998) 0.86
Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. Eur Arch Psychiatry Clin Neurosci (2001) 0.86
Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol (1999) 0.86
HLA system and affective disorders: a sibship genetic study. Tissue Antigens (1978) 0.86
Measurement of the ZZ production cross section and limits on anomalous neutral triple gauge couplings in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 0.86
Search for gluinos in events with two same-sign leptons, jets, and missing transverse momentum with the ATLAS detector in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 0.85
A symptom-specific analysis of the effect of high-frequency left or low-frequency right transcranial magnetic stimulation over the dorsolateral prefrontal cortex in major depression. Neuropsychobiology (2010) 0.85
Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biol Psychiatry (2001) 0.85
Protein kinase A and Rap1 levels in platelets of untreated patients with major depression. Mol Psychiatry (2001) 0.85
Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry (2002) 0.85
Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity. Genes Brain Behav (2010) 0.84
Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J Psychiatr Res (2001) 0.84
Sleep deprivation hastens the antidepressant action of fluoxetine. Eur Arch Psychiatry Clin Neurosci (1997) 0.84
Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J Med Genet (1998) 0.84
Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry (2002) 0.83
Discrimination of amplitude-modulation phase spectrum. J Acoust Soc Am (1999) 0.83
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry (2010) 0.83
Search for dilepton resonances in pp collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2011) 0.83